Ozempic vs Mounjaro vs Wegovy: Which Is Right for You?
Ozempic, Mounjaro, and Wegovy are GLP-1 medications and work in similar ways, but they are not approved for the same things. The comparison is really Semaglutide vs Tirzepatide, the two molecules behind these three brands. Ozempic and Wegovy contain Semaglutide. Mounjaro contains Tirzepatide. Ozempic and Mounjaro are FDA-approved for type 2 diabetes, while Wegovy is FDA-approved for chronic weight management. In the only head-to-head trial run between them, Tirzepatide (Mounjaro) produced more weight loss than Semaglutide (Ozempic and Wegovy).
When comparing Ozempic, Mounjaro, and Wegovy, the biggest differences center on weight-loss results, FDA approvals, side effects, and insurance coverage. If you already know which one fits you, you can talk to a doctor online about weight loss medications and get a prescription the same day if you qualify.
| Ozempic | Wegovy | Mounjaro | |
| Active ingredient | Semaglutide | Semaglutide | Tirzepatide |
| Mechanism | GLP-1 receptor agonist | GLP-1 receptor agonist | Dual GLP-1 + GIP receptor agonist |
| FDA-approved for | Type 2 diabetes | Chronic weight management | Type 2 diabetes |
| Weight loss in the trial | Not approved for weight loss | 14.9% over 68 weeks at 2.4 mg (STEP-1). 20.7% over 72 weeks at 7.2 mg (Wegovy HD, STEP UP)“ | 22.5% over 72 weeks at 15 mg (SURMOUNT-1) |
| Form | Weekly injection (pen) | Weekly injection (pen) or daily oral pill | Weekly injection (pen or vial) |
| Doses | 0.25 mg to 2 mg | 0.25 mg to 2.4 mg injection, 7.2 mg high-dose injection (Wegovy HD), or 25 mg pill | 2.5 mg to 15 mg |
| Manufacturer | Novo Nordisk | Novo Nordisk | Eli Lilly |
| Cash price | $499/mo (NovoCare) | $349/mo injection, $399/mo Wegovy HD, $149–$199/mo pill (NovoCare) | $1,079.77/mo list (no direct self-pay program) |
How Ozempic, Mounjaro, and Wegovy work
All three medications belong to a drug class called GLP-1 receptor agonists. GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. It tells your pancreas to release insulin, slows the rate of stomach emptying, and signals fullness to your brain. The GLP-1 receptor is the docking site on cells where this hormone attaches to do its job.
A GLP-1 receptor agonist is a medication that binds to the same docking site and triggers effects similar to those of the natural hormone, but with stronger and longer-lasting effects. That is how Ozempic, Mounjaro, and Wegovy lower blood sugar and reduce appetite. The differences come from the active ingredient and the number of receptors the drug binds to.
Semaglutide
Ozempic and Wegovy contain the active ingredient semaglutide. Semaglutide binds to the GLP-1 receptor, with about 94% structural homology to native human GLP-1. Ozempic and Wegovy differ in dose and indication. Ozempic is dosed up to 2 mg weekly for type 2 diabetes. Wegovy is dosed up to 2.4 mg weekly for weight management, and the higher dose drives the larger weight loss.
Tirzepatide (Mounjaro)
Mounjaro contains tirzepatide as its active ingredient, a dual agonist. It binds to two receptors simultaneously, the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is a second gut hormone that also influences insulin secretion and fat storage. Because it binds to two receptors, Mounjaro produces greater weight loss than semaglutide.
FDA-approved uses and off-label prescribing
Each of these medications is FDA-approved for specific conditions. Prescribing outside those conditions is legal, but it is not always covered by insurance, and not every doctor will write it.
Ozempic is approved for adults with type 2 diabetes. The label also covers a reduction in major cardiovascular events (heart attack, stroke, or death) and kidney function decline in adults with type 2 diabetes, established heart disease, and chronic kidney disease. Ozempic is often prescribed off-label for weight loss in adults without diabetes, but insurance rarely covers this use.
Wegovy is approved for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with a weight-related comorbidity such as high blood pressure or sleep apnea. It is also approved to help reduce the risk of heart attack, stroke, and cardiovascular death in adults with heart disease who are overweight or obese. In the SELECT trial, Semaglutide lowered the risk of major cardiovascular events by 20% compared to placebo.
Wegovy is also approved for adults with moderate-to-advanced liver fibrosis from MASH (metabolic dysfunction-associated steatohepatitis). In the ESSENCE trial, 63% of patients on Semaglutide showed resolution of steatohepatitis without worsening fibrosis at 72 weeks, compared to 34% on placebo. The approval makes Wegovy the second drug ever approved for MASH with liver fibrosis, and the first GLP-1 for that indication. If you have fatty liver disease along with obesity, this changes the medication picture
A daily oral pill version of Semaglutide was approved by the FDA on December 22, 2025. The 25 mg pill is taken once daily on an empty stomach and is the first oral GLP-1 approved for chronic weight management.
Mounjaro is approved only for type 2 diabetes. If your doctor is prescribing Tirzepatide for weight loss, the prescription should read Zepbound, not Mounjaro. Zepbound is approved for chronic weight management using the same BMI criteria as Wegovy. In December 2024, Zepbound also became the first medication approved for moderate to severe obstructive sleep apnea in adults with obesity.
Ozempic vs Mounjaro vs Wegovy: Weight Loss Results Compared
The weight-loss numbers for these medications come from four large randomized trials conducted by the manufacturers and published in the New England Journal of Medicine.
STEP and SURMOUNT trial data
STEP-1 tested Wegovy in 1,961 adults with obesity but no diabetes. Average weight loss was 14.9% over 68 weeks, compared to 2.4% for placebo. About 86% of people on Wegovy lost at least 5% of their body weight.
In March 2026, the FDA approved a higher-dose Semaglutide injection called Wegovy HD (7.2 mg). In the 72-week STEP UP trial in 1,400 adults with obesity, Wegovy HD produced 20.7% average weight loss, and about one in three patients lost at least 25% of their body weight.
SURMOUNT-1 tested Tirzepatide in 2,539 adults with obesity but no diabetes. At a weekly dose of 15 mg, average weight loss reached 22.5% over 72 weeks. About 91% of people on the highest dose lost at least 5% of body weight, and 36% lost at least 25%. Tirzepide used for weight loss is Zepbound, and not Mounjaro.
Ozempic was not designed for weight loss, so weight loss is a secondary outcome in its diabetes trials. In the SUSTAIN program, adults with type 2 diabetes lost about 6 to 9 pounds on Ozempic over 30 to 56 weeks. That is much lower than the figures above, because the maximum dose is lower than that of Wegovy, and people with diabetes lose less weight on GLP-1s than those without.
Semaglutide vs Tirzepatide: SURMOUNT-5 Results
Semaglutide vs Tirzepatide is the comparison the SURMOUNT-5 trial was designed to answer. It enrolled 751 adults with obesity but no diabetes and ran for 72 weeks. Tirzepatide produced 20.2% weight loss, compared with 13.7% for Semaglutide.
The SURMOUNT-5 result carries more weight than the side-by-side STEP and SURMOUNT-1 numbers, because the comparison is direct. Tirzepatide also won on all five secondary endpoints, which included the percentage of people losing at least 10%, 15%, 20%, and 25% of body weight. If maximum weight loss is what you are after, the SURMOUNT-5 data points to Tirzepatide, but the gap narrowed in 2026. Wegovy HD’s 20.7% in STEP UP is within 1 point of Tirzepatide’s 20.2%, which means the choice now turns more on side-effect tolerance, dosing format, and coverage than on raw pounds lost.
Side effects comparison
When comparing Ozempic vs Wegovy vs Mounjaro side effects, the overall pattern is similar because both medications target the GLP-1 pathway, and tirzepatide additionally targets the GIP receptor. The most common ones are gastrointestinal, and frequency rises with the dose. Most people see side effects ease after the first 4 to 8 weeks as the body adjusts. Neither pattern is consistent enough across trials to call one drug easier than the other. Tolerability varies between individuals, which is why doctors start everyone at the lowest dose and titrate up over weeks.
| Side effect | Ozempic | Wegovy | Mounjaro |
| Nausea | Yes (most common, dose-dependent) | Yes (most common, dose-dependent) | Yes (less than Semaglutide in early weeks) |
| Vomiting | Yes | Yes | Yes |
| Diarrhea | Yes | Yes | Yes |
| Constipation | Yes | Yes | Yes (reported more than Semaglutide) |
| Abdominal pain | Yes | Yes | Yes |
| Fatigue | Yes | Yes | Yes |
| Injection site reaction | Yes (mild) | Yes (mild) | Yes (mild) |
| Boxed Warning: thyroid C-cell tumors | Yes | Yes | Yes |
| Pancreatitis (rare) | Yes | Yes | Yes |
| Gallbladder disease | Yes | Yes | Yes |
| Hypoglycemia risk | Higher (used in T2D, often with insulin) | Lower (used in non-diabetics) | Higher (used in T2D, often with insulin) |
Some people on Mounjaro report more constipation when compared to Wegovy, while Semaglutide tends to cause more nausea in the first few weeks. All three medications carry a Boxed Warning for thyroid C-cell tumors, which is why they are not prescribed to anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
All three medications slow stomach emptying, which can change how quickly other oral medications are absorbed. Tell your doctor about insulin, sulfonylureas, warfarin, oral contraceptives, and any other oral medications before starting a GLP-1.
Ozempic vs Wegovy vs Mounjaro: Cost and insurance coverage in the United States
Cost and insurance coverage are where Ozempic, Wegovy, and Mounjaro diverge the most.
Cash prices without insurance
| Medication | 2026 US cash price | Source |
| Ozempic | $499/month via NovoCare for uninsured adults with T2D | NovoCare |
| Wegovy injection | $349/month standard via NovoCare, $199/month intro for the first two fills | NovoCare |
| Wegovy pill | $149–$199/month via NovoCare | NovoCare |
| Mounjaro | $1,079.77/month list price (no direct self-pay program) | Lilly Pricing Info |
The cost difference between Wegovy and Mounjaro is significant, especially for people paying out of pocket.
How to check your coverage
Coverage depends almost entirely on your diagnosis, not on the molecule. Ozempic is on roughly 82% of commercial formularies because diabetes is broadly covered. Wegovy is on about 1% of ACA marketplace plans. If you have type 2 diabetes, your plan probably covers Ozempic or Mounjaro with a prior authorization. If you do not have diabetes, your plan probably does not cover Wegovy unless your employer has added an obesity rider.
The fastest way to check your insurance coverage is to call the member services number on the back of your insurance card and ask the following questions:
- Is Ozempic, Wegovy, Mounjaro, or Zepbound on my formulary?
- What is the prior authorization criteria?
- What is my copay after approval?
Have your BMI, your A1C, and any comorbidities ready before you call. The same call works for Medicare Part D and most employer plans.
Medicare does not currently pay for any GLP-1 prescribed only for weight loss, although a November 2025 Lilly and US government agreement is opening a $50/month Zepbound option for select Medicare beneficiaries as early as April 2026.
Which Is Better: Ozempic, Wegovy, or Mounjaro?
Choosing between Ozempic vs Mounjaro vs Wegovy is not really about which is the best GLP-1 for weight loss. It is determining which GLP-1 is right for you, given your diagnosis, medical history, and insurance coverage.
Decision checklist
Use this checklist to narrow the choice with your doctor. Each line below points to a likely option, not a guarantee. Final prescribing depends on your medical history and current medications.
- If you have type 2 diabetes and your A1C needs to come down, Ozempic and Mounjaro are both reasonable starting points. Mounjaro tends to drop A1C more in the SURPASS head-to-head trials, while Ozempic has longer cardiovascular outcomes data.
- If you have type 2 diabetes plus a history of heart attack, stroke, or kidney disease, Ozempic carries a label indication for those exact uses, which makes prior authorization easier.
- If you want weight loss and your insurance covers obesity medications, Wegovy is the FDA-approved choice.
- If you want the strongest weight loss with Semaglutide, Wegovy HD at 7.2 mg now reaches 20.7% in trial data, which approaches Tirzepatide’s 20.2%. Wegovy HD is for adults already on the 2.4 mg dose who need more weight loss.
- If you want weight loss and your insurance does not cover it, the cash-pay math favors the Wegovy pill through NovoCare ($149 to $199 per month).
- If you cannot tolerate injections, but want to reduce weight, the daily Wegovy pill is the only oral option in this class for weight loss.
- If you have PCOS with insulin resistance or weight gain, Wegovy or off-label Mounjaro can help with both issues, but neither is FDA-approved for PCOS specifically.
- If you have a personal or family history of medullary thyroid cancer or MEN 2 syndrome, none of these medications is safe for you.
- If you have MASH or moderate-to-advanced liver fibrosis with obesity, Wegovy is the only GLP-1 in this group with a labeled liver indication.
How to get a GLP-1 prescription online
You can reach out to one of our licensed doctors to get the best GLP-1 for weight loss prescribed online. Here is how the process works, once you have downloaded the app and created an account:
- Start by sharing your weight, height, medical history, current medications, and any recent labs in chat.
- The doctor reviews your BMI against the FDA criteria, checks your diabetes status, screens for contraindications such as a personal or family history of thyroid cancer, and confirms whether one of the three medications is appropriate.
- If you qualify, the prescription is sent to your pharmacy of choice for same-day pickup.
- For weight loss specifically, the doctor may write the prescription for Wegovy
- If you have type 2 diabetes, you can get an online prescription for Ozempic or an online prescription for Mounjaro, depending on what your formulary supports.
We are open 24/7 across the US, including New York, Texas, and California. Our doctors can handle refills and switches between GLP-1s if your current medication has stalled, caused side effects, or fallen off your insurance formulary.
Frequently asked questions
Mounjaro (Tirzepatide) produces more weight loss on average. In the SURMOUNT-5 head-to-head trial, Tirzepatide led to 20.2% body weight reduction, compared with 13.7% for Semaglutide (active ingredient for Ozempic and Wegovy), over 72 weeks. Wegovy is the FDA-approved version of Semaglutide for weight loss, and Mounjaro is not. If a doctor is prescribing Tirzepatide for weight management, you will receive Zepbound, not Mounjaro.
Wegovy is dosed higher (up to 2.4 mg weekly versus Ozempic’s 2 mg) and is approved for chronic weight management, which is a separate indication that most insurance plans do not cover the way they cover diabetes. The list prices for both Wegovy and Ozempic are similar, but the cash-pay programs through NovoCare put Wegovy at $349 per month and Ozempic at $499 per month. Out-of-pocket, Wegovy is now cheaper than Ozempic.
Yes, you can switch from Ozempic to Mounjaro. Mounjaro is one of the common alternatives to Ozempic for type 2 diabetes treatment. Switching between GLP-1s is common, often due to insurance changes, side effects, or a weight-loss stall. The new medication starts at its own lowest dose and is titrated up on the same schedule as a new patient. There is no required washout period between weekly GLP-1s, but doctors usually wait one week between the last dose of the old drug and the first dose of the new one.
Weight usually comes back. In the STEP-1 extension study, adults who stopped Semaglutide regained about two-thirds of the weight they had lost within 12 months. These medications work for as long as you take them. Plans to stop should include a slow taper, continued dietary and exercise habits, and follow-up with your doctor to manage the return of appetite.
No, you should not take Ozempic and Mounjaro at the same time. Ozempic and Mounjaro both act on the GLP-1 receptor, and stacking two GLP-1 medications has not been studied for safety. Combining them increases the risk of side effects, particularly nausea and low blood sugar in people with diabetes.
Yes, the active ingredient is identical (Tirzepatide). The difference is the FDA-approved indication. Mounjaro is approved for the treatment of type 2 diabetes. Zepbound is approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. The version your doctor prescribes depends on your medical condition.
Coverage for Wegovy remains rare on commercial plans and is largely excluded by Medicare for weight loss alone. Plans with an employer-added obesity rider are the most likely route to coverage. The March 2024 cardiovascular indication has opened new coverage paths for adults with established heart disease and obesity, since plans that decline weight-loss coverage may still cover Wegovy for heart attack and stroke prevention.
Neither is FDA-approved for PCOS specifically, but both can help with insulin resistance and weight gain that drives PCOS symptoms. In small studies, GLP-1 medications, including Semaglutide and Tirzepatide, have improved insulin sensitivity and menstrual regularity in adults with PCOS, but the evidence is early, and prescribing is off-label. If you have PCOS and a BMI of 30 or higher (or 27 with comorbidity), Wegovy is the labeled choice for weight loss.
